Gainplan’s KalVista Pharmaceuticals KALV Stock Holding History

Gainplan’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-30,000	Closed	-$772K	–	83
2021 Q1	$772K	Buy	+30,000	New	+$788K	0.34%	26

Other funds holding KALV

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Gainplan's KALV Position: Q2 2021 in Review

Gainplan sold out of KalVista Pharmaceuticals (KALV) in Q2 2021, closing a stake of 30,000 shares — an estimated $772K sold.

Gainplan first reported a position in KALV in Q1 2021 and held it in 1 quarter. The position peaked at $772K in Q1 2021. 110 funds tracked by Wall St. Rank hold KALV as of Q2 2021.

Gainplan reported no remaining KalVista Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Gainplan sold 30,000 KalVista Pharmaceuticals shares in Q2 2021, an estimated $772K.
Gainplan first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Gainplan's KalVista Pharmaceuticals position peaked at $772K in Q1 2021.
110 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2021.

Based on Gainplan's 13F filing for Q2 2021, filed 12 Aug 2021.